Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Start your free trial now

Instant access. No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: LASTACAFT

« Back to Dashboard
Lastacaft is a drug marketed by Allergan and is included in one NDA. It is available from three suppliers. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has seventy-five patent family members in forty countries.

The generic ingredient in LASTACAFT is alcaftadine. There are five drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the alcaftadine profile page.

Summary for Tradename: LASTACAFT

Patents:2
Applicants:1
NDAs:1
Suppliers: see list3

Clinical Trials for: LASTACAFT

A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis
Status: Completed Condition: Conjunctivitis, Allergic

A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis
Status: Completed Condition: Conjunctivitis, Allergic

Ocular Allergy Treatment Practical Impact Trial
Status: Recruiting Condition: Allergic Conjunctivitis; Rhinoconjunctivitis

A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy
Status: Active, not recruiting Condition: Allergic Conjunctivitis

A Patient Reported Ocular Comfort Assessment Comparing Bepreve to Lastacaft
Status: Recruiting Condition: Allergic Conjunctivitis

Safety and Efficacy Study of a Eye Drop for Eye Allergy
Status: Completed Condition: Allergic Conjunctivitis

Comparison of Tolerability Between Two Allergy Drops
Status: Enrolling by invitation Condition: Allergic Conjunctivitis

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan
LASTACAFT
alcaftadine
SOLUTION/DROPS;OPHTHALMIC022134-001Jul 28, 2010RXYes8,664,215<disabled><disabled>
Allergan
LASTACAFT
alcaftadine
SOLUTION/DROPS;OPHTHALMIC022134-001Jul 28, 2010RXYes5,468,743<disabled>YY<disabled>
Allergan
LASTACAFT
alcaftadine
SOLUTION/DROPS;OPHTHALMIC022134-001Jul 28, 2010RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: LASTACAFT

Drugname Dosage Strength RLD Submissiondate
alcaftadineOphthalmic Solution0.25%Lastacaft7/30/2014

International Patent Family for Tradename: LASTACAFT

Country Document Number Publication Date
Poland173351Feb 27, 1998
Canada2103242Dec 14, 1992
European Patent Office0588858Mar 30, 1994
Austria250061Oct 15, 2003
Poland170771Jan 31, 1997
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc